A naturalistic evaluation and audit database of agomelatine: clinical outcome at 12 weeks. (14th December 2012)

• Record Type: Journal Article
• Authors: Sparshatt, A.; McAllister Williams, R. H.; Baldwin, D. S.; Haddad, P. M.; Bazire, S.; Weston, E.; Taylor, P.; Taylor, D.
• Is Part Of: Acta psychiatrica Scandinavica. Volume 128:Number 3(2013:Sep.)
• Page Start: 203
• Page End: 211
• Publication Date: 2012-12-14
• Subjects: Psychiatry -- Periodicals; 616.89
• DOI: 10.1111/acps.12044
• Languages: English
• ISSNs: 0001-690X

Abstract

<abstract abstract-type="main" id="acps12044-abs-0001"> <title> <x xml:space="preserve">Abstract</x> </title> <sec id="acps12044-sec-0001" sec-type="section"> <title>Objective</title> <p>To determine the effectiveness of agomelatine in routine clinical practice and explore factors associated with response and continuation.</p> </sec> <sec id="acps12044-sec-0002" sec-type="section"> <title>Method</title> <p>Consecutive patients prescribed agomelatine in participating psychiatric services were included. Patient demographic and outcome data were collected at treatment initiation and then at weeks 4, 8 and 12. Outcomes were analysed with respect to clinical and demographic factors.</p> </sec> <sec id="acps12044-sec-0003" sec-type="section"> <title>Results</title> <p>A total of 110 patients from nine NHS trusts were followed through 12 weeks of treatment. Agomelatine was largely used in difficult‐to‐treat or refractory patients: 83 (75%) had failed to respond to, or relapsed on, prior antidepressants. There were high rates of physical (54.5%) and psychiatric (50.0%) comorbidity. At 12 weeks of treatment, 68 (62%) continued agomelatine treatment. Overall, 69 subjects (62.7%) improved by at least one point of the Clinical Global Impression (severity) scale. Of 42 who discontinued, 23 (56%) discontinued because of lack of efficacy and 10 (24%) due to an adverse event. Of all variables examined, only a history of more than five episodes of depression significantly predicted discontinuation of treatment (OR continuation – 0.36, 95% CI 0.14, 0.95).</p> </sec> <sec id="acps12044-sec-0004" sec-type="section"> <title>Conclusion</title> <p>Agomelatine was effective and generally well tolerated in a cohort of difficult‐to‐treat patients in clinical practice.</p> </sec> </abstract>